Sana Biotechnology
SANA
178 hedge funds and large institutions have $582M invested in Sana Biotechnology in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 66 increasing their positions, 36 reducing their positions, and 21 closing their positions.
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
83% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 36
46% more capital invested
Capital invested by funds: $398M → $582M (+$184M)
15% more funds holding
Funds holding: 155 → 178 (+23)
4.3% more ownership
Funds ownership: 64.52% → 68.82% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less call options, than puts
Call options by funds: $1.48M | Put options by funds: $1.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13M |
| 4 |
Renaissance Technologies
New York
|
+$6.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.72M |
| 2 |
Morgan Stanley
New York
|
-$2.18M |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
-$2.17M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.92M |
| 5 |
Corient Private Wealth
Miami,
Florida
|
-$1.15M |
SANA Hedge Fund Activity: Q3 2025 in Review
178 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2025, worth a combined $582M — up 46% from $398M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new SANA positions and 21 closed out — a net gain of 25 holders — while 66 added to existing stakes and 36 trimmed.
The largest buyer was State Street, adding an estimated $13.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.72M.
- 178 institutional investors held Sana Biotechnology (SANA) as of Q3 2025, up from 155 in Q2 2025.
- Funds reported $582M of Sana Biotechnology stock for Q3 2025, up 46% quarter-over-quarter.
- 46 funds opened new Sana Biotechnology positions in Q3 2025 and 21 closed out, a net change of +25 holders.
- The largest Sana Biotechnology buyer in Q3 2025 was State Street, an estimated $13.8M added.
- The largest Sana Biotechnology seller in Q3 2025 was T. Rowe Price Associates, an estimated $8.72M sold.
Based on aggregated 13F filings for Q3 2025.